Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy

Autor: Piero Picci, Michela Versari, Gaetano Bacci, Antonio Briccoli, Franca Fagioli, Alessandra Longhi
Přispěvatelé: Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P.
Rok vydání: 2005
Předmět:
Zdroj: European Journal of Cancer. 41:2836-2845
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2005.08.026
Popis: Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different protocols of neoadjuvant chemotherapy. The rate of limb salvage increased from 20% to 71%. The 5-year event-free survival (EFS) and overall survival (OS) were 57% and 66%, respectively. The 10-year EFS and OS were 52% and 57%, respectively, and the results significantly correlated with serum alkaline phosphatase levels; the type of chemotherapy (adjuvant vs neoadjuvant); and with histologic response to pre-operative treatment. Aggressive chemotherapy and surgery could cure about the 60% of patients with osteosarcoma of the extremity. However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended.
Databáze: OpenAIRE